CTOs on the Move

Chugai Pharma

www.chugai-pharm.com

 
Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.chugai-pharm.com
  • 300 Connell Drive Suite 3100
    Berkeley Heights, NJ USA 07922
  • Phone: 908.516.1350

Executives

Name Title Contact Details

Similar Companies

New York State Pharmacist: Century Ii

New York State Pharmacist: Century Ii is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dainippon Sumitomo Pharma America Holdings

Dainippon Sumitomo Pharma America Holdings is a Fort Lee, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ostomy

RPS Pharmacy is an affiliate of Millenium Pharmaceuticals and as such, we are committed to quality healthcare with an honest approach that values patient privacy and security. All information provided to us is legally protected under the doctor-patient

Union Center Pharmacy

Union Center Pharmacy is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.